Comparison of baseline characteristics stratified by the presence of infarct (n=156)
| Variable | Infarct (n=97) | Non-infarct (n=59) | P value |
| Age, median (IQR) | 72 (61–80) | 69 (60–80) | 0.822 |
| Female, n (%) | 49 (51) | 32 (54) | 0.652 |
| White, n (%) | 89 (92) | 58 (98) | 0.387 |
| Baseline NIHSS, median (IQR) | 16 (10–21) | 16 (11–20) | 0.987 |
| Glucose, mg/dL, median (IQR) | 129 (109–166) | 120 (108–142) | 0.084 |
| Medical history, n (%) | |||
| Hypertension | 80 (83) | 31 (53) | 0.001** |
| Atrial fibrillation | 29 (30) | 19 (32) | 0.762 |
| Diabetes | 27 (28) | 14 (24) | 0.572 |
| Coronary artery disease | 20 (21) | 7 (12) | 0.161 |
| Prior stroke or transient ischemic attack | 13 (13) | 7 (12) | 0.781 |
| Smoking | 37 (38) | 19 (32) | 0.453 |
| Premorbid medications, n (%) | |||
| Antiplatelet drugs | 36 (37) | 21 (36) | 0.848 |
| Anticoagulants | 14 (14) | 10 (17) | 0.673 |
| Anti-diabetic drugs | 18 (19) | 8 (14) | 0.417 |
| Antihypertensives | 65 (67) | 35 (60) | 0.332 |
| Statins | 33 (34) | 25 (42) | 0.295 |
| Pre-EVT imaging | |||
| Baseline ASPECTS | 8 (6–9) | 8 (7–9) | 0.474 |
| CTP time-to-maximum >6 s, mL, median (IQR) | 110 (78–147) † | 105 (65–135)‡ | 0.357 |
| CTP time-to-maximum >10 s, mL, median (IQR) | 43 (18–87) † | 40 (11–79)‡ | 0.388 |
| Treatment characteristics | |||
| Intravenous tPA, n (%) | 51 (53) | 34 (58) | 0.653 |
| Time from LKW to groin puncture, median (IQR) | 302 (242–555) | 362 (251–668) | 0.510 |
| Time from LKW to reperfusion, median (IQR) | 376 (300–604) | 397 (303–706) | 0.723 |
| General anesthesia, n (%) | 58 (60) | 25 (43) | 0.037* |
| Initial occlusion on DSA, n (%) | 0.530 | ||
| Internal carotid artery | 14 (14) | 7 (12) | |
| Middle cerebral artery M1 segment | 66 (68) | 42(71) | |
| Middle cerebral artery M2 segment | 14 (14) | 10 (17) | |
| Middle cerebral artery M3 segment | 3 (3) | 0 (0) | |
| Evidence of leptomeningeal collaterals, n (%) | 56 (43) | 67 (72) | 0.001* |
| Use of balloon guide catheter, n (%) | 3 (3) | 1 (2) | 0.989 |
| Stent retriever characteristics, median (IQR) | |||
| Diameter, mm | 6 (4–6) | 4 (4–6) | 0.048* |
| Length, mm | 37 (25–40) | 30 (20–40) | 0.046* |
| Intra-arterial tPA | 0 (0) | 1 (2) | 0.378 |
| Emboli after TICI 2b revascularization | |||
| Number of distal emboli, median (IQR) | 1 (1–2) | 1 (1–2) | 0.667 |
| ≥1 distal embolus, n (%) | 19 (32) | 32 (33) | 0.919 |
| Occluded vessel diameter, mm, median (IQR) | 1.08 (0.85–1.3) | 1.04 (0.8–1.3) | 0.662 |
| Follow-up characteristics | |||
| Intracranial hemorrhage, n (%) | 10 (10) | 6 (10) | 0.978 |
| Death, n (%) | 22 (23) | 7 (12) | 0.084 |
| Discharge mRS, n (%) | 0.002* | ||
| 0–2 | 13 (13) | 20 (34) | |
| 3–6 | 84 (87) | 39 (66) | |
| 90-day mRS, n (%) | 0.046* | ||
| 0–2 | 34 (39)§ | 32 (55)¶ | |
| 3–6 | 53 (61)§ | 26 (45)¶ |
*Statistical significance P<0.05.
†n=61.
‡n=45.
§n=87.
¶n=58.
ASPECTS, Alberta Stroke Program Early CT Score; CTP, CT perfusion; DSA, digital subtraction angiography; EVT, endovascular thrombectomy; LKW, last known well; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TICI, Thrombolysis In Cerebral Infarction; tPA, tissue plasminogen activator.